Supporting a role for HMGB1 as an independent prognostic marker, a study of HMGB1 serum levels in 105 ovarian carcinoma patients demonstrated that increased levels of HMGB1 were found in patients with more advanced stage disease and were at higher levels in cancer patients compared with healthy controls [21]. The gene discussed is HMGB1; the disease is ovarian carcinoma.